Head-to-head evidence
CKD-701 vs KSI-301
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Age-Related Macular Degeneration
Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline
CKD-701
Developed by Chong Kun Dang Pharmaceutical
NCT04857177 · Phase 3 · completed
In this randomized, double-blind, active-controlled Phase 3 trial, 312 patients with wet AMD were randomized to CKD-701 or the reference biologic Lucentis (ranibizumab). The proportion of patients avoiding significant vision loss was nearly identical between groups (97.95% vs 98.62%), and the difference fell entirely within the trial's prespecified equivalence margin.
KSI-301
Developed by Kodiak Sciences Inc.
NCT04964089 · Phase 3 · completed
This was a randomized, triple-masked, active-controlled trial with 276 participants receiving KSI-301 and 281 receiving aflibercept. The hard clinical primary endpoint, change in best-corrected visual acuity, met the prespecified non-inferiority criterion: the adjusted difference was -2.1 ETDRS letters (95% CI -3.88 to -0.29; p=0.0083).
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CKD-701's landscape · KSI-301's landscape